- Home
- RMCO vs MTVA Comparison
RMCO vs MTVA Comparison
Compare RMCO & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- MTVA
- Stock Information
- Founded
- RMCO 2021
- MTVA 2014
- Country
- RMCO United States
- MTVA United States
- Employees
- RMCO N/A
- MTVA N/A
- Industry
- RMCO Multi-Sector Companies
- MTVA
- Sector
- RMCO Miscellaneous
- MTVA
- Exchange
- RMCO Nasdaq
- MTVA NYSE
- Market Cap
- RMCO 14.9M
- MTVA 7.1M
- IPO Year
- RMCO N/A
- MTVA N/A
- Fundamental
- Price
- RMCO $1.10
- MTVA $0.71
- Analyst Decision
- RMCO
- MTVA Strong Buy
- Analyst Count
- RMCO 0
- MTVA 1
- Target Price
- RMCO N/A
- MTVA $12.00
- AVG Volume (30 Days)
- RMCO 62.4K
- MTVA 1.5M
- Earning Date
- RMCO 05-23-2025
- MTVA 05-20-2025
- Dividend Yield
- RMCO N/A
- MTVA N/A
- EPS Growth
- RMCO N/A
- MTVA N/A
- EPS
- RMCO N/A
- MTVA N/A
- Revenue
- RMCO $807,089.00
- MTVA N/A
- Revenue This Year
- RMCO N/A
- MTVA N/A
- Revenue Next Year
- RMCO N/A
- MTVA N/A
- P/E Ratio
- RMCO N/A
- MTVA N/A
- Revenue Growth
- RMCO 65.21
- MTVA N/A
- 52 Week Low
- RMCO $0.74
- MTVA $0.71
- 52 Week High
- RMCO $1.59
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- RMCO 46.19
- MTVA N/A
- Support Level
- RMCO $1.06
- MTVA N/A
- Resistance Level
- RMCO $1.22
- MTVA N/A
- Average True Range (ATR)
- RMCO 0.11
- MTVA 0.00
- MACD
- RMCO -0.01
- MTVA 0.00
- Stochastic Oscillator
- RMCO 13.46
- MTVA 0.00
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.